0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Liu (RCT) -3% 1.03 [0.10-11.1] death 2/87 1/45 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.98 Early treatment -3% 1.03 [0.10-11.1] 2/87 1/45 3% higher risk All studies -3% 1.03 [0.10-11.1] 2/87 1/45 3% higher risk 1 ropeginterferon alfa-2b COVID-19 study c19early.org November 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.98 Effect extraction pre-specified(most serious outcome) Favors ropeginterferon alfa-2b Favors control
Ropeginterferon Alfa-2b is a long-acting, mono-pegylated recombinant Type I interferon biologic administered via subcutaneous injection.
May 21
2024
 Liu et al., Infectious Diseases and Therapy, doi:10.1007/s40121-024-00992-5 A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19
90% lower ventilation (p=0.04), 3% higher need for oxygen therapy (p=1), and 4% improved recovery (p=1). RCT 132 hospitalized moderate COVID-19 patients in Taiwan showing higher rates of viral clearance or discharge by day 11 with ropeginterferon alfa-2b. The ropeginterferon alfa-2b group also showed higher rates of improvement in lung infil..